Key Facts
- The Indian Patent Office rejected a patent application filed by the US-based Global Alliance for TB Drug Development (TB Alliance) for the BPaL regimen, a treatment for drug-resistant tuberculosis (MDR-TB).
- BPaL is a six-month, all-oral treatment regimen recommended by the World Health Organization (WHO) for drug-resistant TB. It comprises bedaquiline, pretomanid, and linezolid.
- The BPaLM variant adds moxifloxacin and has an 89% treatment success rate, compared with 52–75% for standard longer regimens that often require painful injections.
- India accounts for nearly 25% of all global TB cases, with an incidence rate of 187 cases per 100,000 people in 2024.
- India missed its ambitious 2025 target to eliminate tuberculosis under the National Tuberculosis Elimination Programme (NTEP). However, TB incidence fell by 21% between 2015 and 2024.
Grounds for Patent Rejection
- Civil society organisations filed pre-grant oppositions under Section 25(1) of the Patents Act, 1970, arguing that clinical trials from 2015 had already disclosed the medicines in combination.
- The Patent Controller cited:
- Lack of novelty
- Absence of an inventive step
- Insufficient disclosure
- Statutory provisions invoked:
- Section 3(d): Restricts patents on new forms of known substances unless they demonstrate significantly enhanced efficacy. It is a key safeguard against evergreening, i.e., extending patent protection through minor modifications.
- Section 3(e): Excludes a mere admixture of known substances from patentability.
- Section 3(i): Excludes methods of treating human beings from patentability.
Significance
- Removing the patent barrier allows generic manufacturers to produce the drugs, fostering competition and reducing prices.
- The government can procure cheaper medicines for NTEP, effectively expanding the programme's reach within the same budget.
- The decision aligns with the Right to Health under Article 21. In Parmanand Katara v. Union of India (1989), the Supreme Court emphasised the State's duty to protect human life.
Regulatory Caveat
- Patent rejection does not automatically authorise generic sales.
- Manufacturers still require marketing approval from the Central Drugs Standard Control Organisation (CDSCO) and must align with national treatment guidelines and quality checks.
Exam Relevance
- Prelims: WHO TB regimens, Patents Act provisions, NTEP, TB burden, CDSCO.
- Mains: IPR and public health, access to medicines, Article 21, regulatory governance, TB elimination strategy.